K. Lewis

发表

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

J. Sosman, A. Ribas, P. Hwu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Basal cell skin cancer, version 1.2016: Clinical practice guidelines in oncology

T. Olencki, R. Cheney, A. Ho, 2016 .

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

K. Flaherty, J. Sosman, I. Puzanov, 2012, The New England journal of medicine.

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, N. Le, 2012, The Lancet. Oncology.

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

R. Dummer, R. Plummer, L. Dirix, 2015, The Lancet. Oncology.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Troy Guthrie, Kevin Harrington, Lee Cranmer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity

J. Pearson, G. Mann, N. Hayward, 2020, Nature Communications.

Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma

J. Larkin, M. Hurwitz, M. Sznol, 2019 .

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Jon Richards, Michael B Atkins, M. Atkins, 2010, Clinical Cancer Research.

420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

M. Hurwitz, M. Sznol, I. Puzanov, 2020 .

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.

Merkel cell carcinoma, version 1.2014.

T. Olencki, R. Cheney, A. Ho, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.

M. Atkins, P. Durani, F. Hodi, 2021, The Lancet. Oncology.

Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review

K. Lewis, R. Gonzalez, Sonia Okuyama, 2010, Core evidence.

Anti-CTLA4 antibody therapy related complications on FDG PET/CT.

R. Gonzalez, K. Lewis, P. Koo, 2014, Clinical nuclear medicine.

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

Ed S. McCarron, C. Slingluff, K. Lewis, 2021, Journal for ImmunoTherapy of Cancer.

Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy

Jennifer D. Hintzsche, M. McCarter, Jihye Kim, 2020, Cancers.

A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making

M. McCarter, K. Lewis, R. Torphy, 2019, Journal of surgical oncology.

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

D. Camidge, S. Leong, K. Lewis, 2011, Investigational New Drugs.

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib.

D. Schadendorf, P. Ascierto, M. Mandalà, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapeutic options in cutaneous melanoma: latest developments

R. Amaria, R. Gonzalez, K. Lewis, 2011, Therapeutic advances in medical oncology.

Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.

D. Morton, R. Gonzalez, K. Lewis, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Merkel Cell Carcinoma , Version 1 . 2018 Clinical Practice Guidelines in Oncology

T. Olencki, I. Puzanov, A. Ho, 2018 .

Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

K. Flaherty, R. Kurzrock, N. Le, 2014 .

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

R. Sullivan, K. Flaherty, Douglas B. Johnson, 2022, Investigational New Drugs.

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

C. Rudin, A. Jimeno, S. Gettinger, 2013, Clinical Cancer Research.

Targeting myeloid‐derived suppressor cells using all‐trans retinoic acid in melanoma patients treated with Ipilimumab

Kimberly R. Jordan, M. McCarter, K. Lewis, 2018, International immunopharmacology.

BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).

K. Flaherty, J. Sosman, M. Sznol, 2013 .

Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma

R. Sullivan, F. Hodi, R. Gonzalez, 2016 .

Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts

Brendan, J. McQuade, M. Hurwitz, 2021, Journal of Translational Medicine.

The absent-minded professor: an unusual complication of melanoma.

K. Lewis, R. Kudchadkar, R. Gonzalez, 2008, Oncology.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Immunosuppressive Dendritic and Regulatory T Cells are Upregulated in Melanoma Patients

M. McCarter, B. Palmer, R. Gonzalez, 2007, Annals of Surgical Oncology.

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma

G. Linette, J. Sosman, G. Schwartz, 2017, Journal of Cancer Research and Clinical Oncology.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

M. Atkins, F. Hodi, H. Tawbi, 2018, The New England journal of medicine.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

A. Hauschild, D. Schadendorf, I. Lowy, 2021, Journal for ImmunoTherapy of Cancer.

A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.

D. Davar, J. Kirkwood, H. Kluger, 2018 .

Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.

J. Larkin, J. Kirkwood, H. Kluger, 2020 .

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

R. Sullivan, K. Flaherty, Douglas B. Johnson, 2022, Investigational New Drugs.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

Jennifer D. Hintzsche, M. McCarter, Jihye Kim, 2017, Melanoma research.

Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts

Infante, K. Sikorska, M. Sznol, 2020, Journal of Translational Medicine.

Remote-onset alopecia areata attributed to ipilimumab.

K. Lewis, T. Alkousakis, D. Pearson, 2019, Cutis.

BRAF/MEK inhibitor-induced remission of primary cutaneous myoepithelial carcinoma after local recurrence

K. Lewis, Mariah R. Brown, J. Guidry, 2020, JAAD case reports.

A Case of Merkel Cell Carcinoma March

B. Kavanagh, K. Lewis, Kyle E. Rusthoven, 2017 .

A case of Merkel cell carcinoma.

B. Kavanagh, K. Lewis, Kyle E. Rusthoven, 2008, Oncology.

Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients withBRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial

P. Ascierto, H. Gogas, P. Rutkowski, 2020 .

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

M. Atkins, F. Hodi, H. Tawbi, 2019, Journal of Clinical Oncology.

Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

D. Schadendorf, R. Dummer, J. Wolchok, 2022, Journal of Clinical Oncology.

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

A. Hauschild, S. Arron, C. Rudin, 2015, Journal of the American Academy of Dermatology.

Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease.

A. Hauschild, D. Schadendorf, R. Dummer, 2014, European journal of cancer.

D. Schadendorf, P. Ascierto, P. Rutkowski, 2019, European journal of cancer.

Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors.

M. McCarter, A. van Bokhoven, K. Lewis, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

M. Hurwitz, M. Sznol, I. Puzanov, 2021, Journal of Clinical Oncology.

IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients

Derek E. Smith, Kimberly R. Jordan, M. McCarter, 2019, Front. Oncol..

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

M. Atkins, F. Hodi, H. Tawbi, 2021, Neuro-oncology.

789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)

J. Kirkwood, P. Hari, H. Kluger, 2022, Regular and Young Investigator Award Abstracts.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

G. Linette, J. Wolchok, J. Sosman, 2014, JAMA.

Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial

R. Dummer, K. Lewis, Aaron S Farberg, 2021, Dermatology and Therapy.

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study

R. Dummer, R. Plummer, L. Dirix, 2019, The British journal of dermatology.

Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update

S. D'Angelo, K. Lewis, C. Lebbé, 2017 .

K. Peris, K. Lewis, A. Sekulic, 2021 .

Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

T. Olencki, I. Puzanov, A. Ho, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis

R. Gutzmer, K. Lewis, C. Robert, 2021, Dermatology and Therapy.

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

A. Ribas, I. Puzanov, A. Daud, 2019, Clinical Cancer Research.

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up

G. Linette, S. D'Angelo, K. Lewis, 2021, ESMO open.

Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update.

A. Hauschild, J. Hainsworth, L. Dirix, 2012 .

PI-88: a novel inhibitor of angiogenesis.

R. Gonzalez, K. Lewis, R. Kudchadkar, 2008, Expert opinion on investigational drugs.

Current Status and Future Prospects of Gene Therapy

R. Gonzalez, K. Lewis, Tahl N Humes, 2005 .

Increased survival from stage IV melanoma associated with fewer regulatory T Cells.

M. McCarter, B. Palmer, R. Gonzalez, 2009, The Journal of surgical research.

Dermatofibrosarcoma protuberans, version 1.2014.

T. Olencki, R. Cheney, A. Ho, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Basal Cell Skin Cancer , Version 1 . 2016 Clinical Practice Guidelines in Oncology

T. Olencki, R. Cheney, A. Ho, 2016 .

PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma

A. Hauschild, D. Schadendorf, C. Chung, 2018, The New England journal of medicine.

Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Aleksandar Sekulic, Daniel Berg, Wade L Thorstad, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Aleksandar Sekulic, Michael R Migden, Axel Hauschild, 2012, The New England journal of medicine.

Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study

R. Dummer, R. Plummer, L. Dirix, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin

K. Lewis, Mariah R. Brown, R. Danhof, 2018, American Journal of Clinical Dermatology.

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.

R. Dummer, R. Plummer, L. Dirix, 2016, Journal of the American Academy of Dermatology.

Treatment with two diff erent doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma ( BOLT ) : a multicentre , randomised , double-blind phase 2 trial

R. Dummer, R. Plummer, L. Dirix, 2015 .

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

C. Berking, A. Hauschild, D. Schadendorf, 2020, The Lancet. Oncology.

Metastatic basal cell carcinoma : Prognosis dependent on anatomic site and spread of disease qq

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

Lymphangiomatosis Masquerading as Metastatic Melanoma

M. McCarter, R. Quaife, K. Lewis, 2006, The American surgeon.

Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature

R. Gonzalez, K. Lewis, M. Fujita, 2009, International journal of dermatology.

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

R. Sullivan, F. Hodi, H. Tawbi, 2019, Nature Medicine.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Yu Shyr, Fei Ye, Donald Lawrence, 2012, The New England journal of medicine.

ABT-737 synergizes with Bortezomib to kill melanoma cells

Yuchun Luo, David A. Norris, R. Gonzalez, 2011, Biology Open.

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

K. Lewis, C. Lebbé, M. Milella, 2018, Journal of Immunotherapy for Cancer.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

G. Linette, K. Lewis, C. Lebbé, 2016, The Lancet. Oncology.

Bridging the transition from cancer patient to survivor: pilot study results of the Cancer Survivor Telephone Education and Personal Support (C-STEPS) program.

M. Chesney, K. Lewis, Z. Tran, 2013, Patient education and counseling.

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

J. Larkin, J. Kirkwood, H. Kluger, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

Parantu K. Shah, G. Linette, K. Lewis, 2020, Journal for immunotherapy of cancer.

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

John Kirkwood, Eric Whitman, Lee Cranmer, 2011, Investigational New Drugs.

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

H. Beltran, A. Mansfield, C. Chung, 2021, npj Precision Oncology.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

A. Hauschild, S. Puig, R. Dummer, 2021, The Lancet. Oncology.

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

P. Ascierto, H. Gogas, P. Rutkowski, 2020, The Lancet.

A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.

J. Kirkwood, K. Lewis, W. Samlowski, 2007 .

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

N. Agarwal, E. Lam, T. Olencki, 2014, Journal of immunotherapy.

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

S. Patel, K. Lewis, R. Joseph, 2020, Cancers.

Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result.

M. McCarter, D. Gao, C. Gajdos, 2013, JAMA surgery.

Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection

M. McCarter, K. Lewis, R. Torphy, 2021, Annals of Surgical Oncology.

Vismodegib in basal cell carcinoma.

A. Jimeno, R. Amaria, K. Lewis, 2012, Drugs of Today.

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma

D. Schadendorf, A. Pavlick, K. Lewis, 2018, Investigational New Drugs.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

A. Ribas, I. Puzanov, A. Daud, 2014, The Lancet. Oncology.

New targeted therapies in melanoma.

R. Gonzalez, K. Lewis, R. Kudchadkar, 2013, Cancer control : journal of the Moffitt Cancer Center.

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, The Lancet. Oncology.

Side Population Cells from Human Melanoma Tumors Reveal Diverse Mechanisms for Chemoresistance

M. McCarter, N. Ahn, R. Spritz, 2012, The Journal of investigative dermatology.

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Paul D. Smith, D. Camidge, R. Agarwal, 2010, Clinical Cancer Research.

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

K. Flaherty, J. Sosman, I. Puzanov, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma

G. Linette, M. Schlichting, K. Lewis, 2019, Cancer Immunology, Immunotherapy.

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

G. Linette, K. Lewis, C. Lebbé, 2018 .

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

G. Linette, J. Sosman, J. Kirkwood, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors.

R. Gonzalez, K. Lewis, R. Kudchadkar, 2012, Seminars in oncology.

Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again

K. Lewis, Christina Davis, 2022, Therapeutic advances in medical oncology.

Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

C. Berking, A. Hauschild, D. Schadendorf, 2019, Journal of Clinical Oncology.

Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)

A. Hauschild, I. Lowy, K. Lewis, 2021 .

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

A. Hauschild, K. Peris, G. Yancopoulos, 2020 .

42-month follow-up of sonidegib efficacy and safety in advanced basal cell carcinoma: Final analysis from BOLT.

K. Lewis, M. Migden, 2018 .

Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.

A. Hauschild, A. Gesierich, J. Hainsworth, 2014 .

Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.

V. Velcheti, M. Ernstoff, K. Lewis, 2022, Journal of Clinical Oncology.

Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.

M. McCarter, A. Baron, K. Lewis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1125PPATIENT-REPORTED QUALITY OF LIFE (QOL) WITH SONIDEGIB (LDE225) IN ADVANCED BASAL CELL CARCINOMA (BCC).

L. Dirix, R. Gutzmer, K. Lewis, 2014, Annals of Oncology.

Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

D. Schadendorf, P. Ascierto, M. Mandalà, 2018, The Lancet. Oncology.

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

K. Flaherty, J. Sosman, Douglas B. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.

R. Elashoff, R. Gonzalez, K. Lewis, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma

S. Arron, K. Lewis, A. Sekulic, 2016, Oncotarget.

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Michael E. Egger, J. Kirkwood, P. Hari, 2022, Journal for ImmunoTherapy of Cancer.

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

J. Kirkwood, H. Kluger, K. Lewis, 2021, Journal of Clinical Oncology.

Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients

K. Lewis, P. Nghiem, M. Shinohara, 2020, JAAD case reports.

Adjuvant peginterferon alfa-2b therapy in stage III melanoma

R. Amaria, K. Lewis, A. Scott, 2011 .

A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma

J. Kirkwood, K. Lewis, W. Samlowski, 2007 .

Novel therapies in melanoma.

R. Amaria, K. Lewis, R. Gonzalez, 2011, Immunotherapy.

The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib

K. Lewis, T. Medina, Karl D Lewis, 2016, OncoTargets and therapy.

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

A. Abernethy, A. Ribas, R. Gonzalez, 2012, Journal of Translational Medicine.

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

A. Hauschild, K. Flaherty, P. Ascierto, 2019, British Journal of Cancer.

Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases

Derek E. Smith, Robin Saiki, L. Gaspar, 2018, Journal of Neuro-Oncology.

CO14. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC)

A. Hauschild, S. Arron, C. Rudin, 2011 .

A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.

J. Wolchok, A. Pavlick, K. Lewis, 2014, European journal of cancer.

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.

M. McCarter, D. Gao, K. Lewis, 2021 .

Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control

B. Kavanagh, D. Raben, K. Lewis, 2010, Radiation oncology.

18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

G. Linette, K. Lewis, C. Lebbé, 2018 .

Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma.

M. McCarter, W. Franklin, K. Lewis, 2006, American journal of surgery.

Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.

J. Berlin, A. Daud, K. Lewis, 2017 .

Metastatic melanoma in the breast: A report of 27 cases

K. Lewis, R. Gonzalez, W. Robinson, 2006, Journal of surgical oncology.

A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes.

M. McCarter, D. Gao, K. Lewis, 2012, Immunotherapy.

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

D. V. Von Hoff, G. Weiss, M. Jeffers, 2013, Clinical Cancer Research.

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials

A. Hauschild, K. Flaherty, P. Ascierto, 2018, JAMA oncology.

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

J. Larkin, J. Kirkwood, H. Kluger, 2019, Journal of Clinical Oncology.

Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to Entrectinib.

R. Doebele, K. Lewis, J. Christiansen, 2017, JCO precision oncology.

Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, Journal of Clinical Oncology.

Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.

R. Sullivan, F. Hodi, P. Hwu, 2017 .

Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass.

M. McCarter, D. Raben, K. Lewis, 2006, Oncology.

A Phase II Study of Biochemotherapy for Advanced Melanoma Incorporating Temozolomide, Decrescendo Interleukin-2 and GM-CSF

P. Gibbs, A. Baron, R. Gonzalez, 2005, Cancer investigation.

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

A. Hauschild, K. Flaherty, P. Ascierto, 2020, Journal of Translational Medicine.

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

A. Jimeno, D. Camidge, K. Lewis, 2013, Investigational New Drugs.

Association of sentinel lymph node diameter with melanoma metastasis.

M. McCarter, C. Gajdos, K. Lewis, 2016, American journal of surgery.

Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.

K. Flaherty, J. Sosman, I. Puzanov, 2012 .

Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM).

J. Kirkwood, C. Watkins, L. Demidov, 2022, Journal of Clinical Oncology.

Alopecia And Chemotherapy

K. Lewis, D. Welch, 1980, The American journal of nursing.

Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.

V. Sondak, J. Kirkwood, A. Ribas, 2022, JAMA oncology.

Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.

V. Sondak, M. Knopp, J. Kirkwood, 2021, Cancer discovery.

436PDPreliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors

H. Beltran, F. Kaye, A. Mansfield, 2017 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.

G. Linette, K. Lewis, C. Lebbé, 2016 .

A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.

H. Beltran, A. Mansfield, C. Chung, 2020 .

Targeting MDSCs using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma

Kimberly R. Jordan, M. McCarter, D. Gao, 2021 .

Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma

Sarah M Kreidler, R. Amaria, R. Gonzalez, 2016, Nuclear medicine communications.

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.

A. Hauschild, K. Flaherty, P. Ascierto, 2019, European journal of cancer.

PI-88: a novel inhibitor of angiogenesis

R. Gonzalez, K. Lewis, R. Kudchadkar, 2008 .

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.

A. Daud, K. Lewis, M. Riese, 2018 .

Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma.

A. Ribas, I. Puzanov, A. Daud, 2016 .

A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma

R. Gonzalez, K. Lewis, S. Legha, 2006, Investigational New Drugs.

LBA7_PRBRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence

D. Schadendorf, P. Ascierto, M. Mandalà, 2017 .

Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study.

P. Ascierto, P. Queirolo, R. Gutzmer, 2020 .

PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.

D. Schadendorf, P. Ascierto, G. Boland, 2022, Future oncology.

Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2012 .

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).

R. Sullivan, E. Rasmussen, Douglas B. Johnson, 2017 .

SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).

A. Ribas, Kevin B. Kim, R. Gonzalez, 2017 .

Vemurafenib: the road to personalized medicine in melanoma.

A. Jimeno, R. Amaria, K. Lewis, 2012, Drugs of today.

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.

I. Lowy, K. Papadopoulos, J. Crown, 2023, Journal of Clinical Oncology.

Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM).

A. Hauschild, K. Flaherty, P. Ascierto, 2017 .

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

G. Linette, M. Ross, K. Harrington, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC)

R. Dummer, L. Dirix, R. Gutzmer, 2014 .

Abstract B238: A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma

A. Jimeno, R. Camidge, S. Leong, 2009 .

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

A. Ribas, I. Puzanov, A. Daud, 2014, The Lancet. Oncology.

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Paul D. Smith, D. Camidge, R. Agarwal, 2010, Clinical Cancer Research.

Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.

A. Hauschild, C. Rudin, J. Hainsworth, 2014 .

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

K. Flaherty, J. Sosman, I. Puzanov, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma.

P. Ascierto, H. Gogas, P. Rutkowski, 2020, Journal of Clinical Oncology.

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study

K. Lewis, J. Goldman, S. Rothenberg, 2022, Clinical Cancer Research.